Kowa Pharmaceuticals America

About

Kowa Pharmaceuticals America stands as a leading pharmaceutical development and commercialization company based in Montgomery, Alabama, serving as the United States division of the globally recognized Kowa Company, Ltd., established in 1894. Since its founding in 2008, the company has dedicated itself to improving medical care through innovative drug development and commercialization of safe, effective healthcare products across the American market. The organization operates through three specialized divisions: Kowa Pharmaceuticals America, Kowa Research Institute, and Kowa Science Institute, enabling comprehensive pharmaceutical research, development, and market delivery. Their clinical development expertise spans cardiovascular therapeutics, dyslipidemia management, type 2 diabetes treatment, atherosclerosis research, ophthalmology solutions, and anti-inflammatory agents. Kowa Pharmaceuticals America has successfully brought LIVALO pitavastatin to market, a therapeutic now approved in 45 countries worldwide, demonstrating their capability to develop globally recognized pharmaceutical products. Their manufacturing approach emphasizes rigorous compliance standards, advanced sales representative training programs, and patient-centered solution development. The company leverages extensive scientific discovery translation capabilities, transforming research findings into potential therapies through systematic clinical development processes. Their commitment to collaboration and strong compliance culture positions them as a trusted partner in pharmaceutical manufacturing and distribution, consistently delivering value-driven medicines that address critical healthcare needs across diverse therapeutic areas while maintaining the highest quality standards.